Genotropin GoQuick Special Precautions

In growth hormone deficiency secondary to treatment of a malignant disease, it is recommended to pay attention to sign of relapse of the malignancy.
Patients with diabetes mellitus may require adjustment of their antidiabetic therapy.
It has been reported that some patients may develop hypothyroidism during growth hormone treatment which should be considered.
Therapy with Genotropin should be directed by physicians who are experienced in the diagnosis and management of patients with growth hormone deficiency.
Because human growth hormone may induce state of insulin resistance, patients should be observed of evidence of glucose intolerance.
Excessive glucocorticoid therapy may inhibit the growth-promoting effect of human growth hormone.
Patients with coexisting ACTH deficiency should have their glucocorticoid replacement dose carefully adjusted to avoid inhibitory effect on growth.
Hypothyroidism may develop during treatment with human growth hormone, and inadequate treatment of hypothyroidism may prevent optimal response to human growth hormone. Therefore, patients should have periodic thyroid function tests and be treated with thyroid hormone when indicated.
Patients with endocrine disorders, including growth hormone deficiency, may develop slipped capital epiphysis more frequently.
Any child with the onset of a limp during growth hormone therapy should be evaluated.
Clinical studies indicated that the treatment with Genotropin for the acute catabolism, including pre- and postoperative treatment, critically ill patients and burn patients, has been reported that the side effect of Jakob-Creutzfeld syndrome (subacute spongioform encephalopathy), which is a slow-virus disease in the central nervous system characterized by the progressive dementia, myoclonic convulsion which attacks adults and the elderly, and can cause death. Therefore, Genotropin is not recommended to use for those indications.
Note: The diagnosis of growth hormone deficiency should be verified before Genotropin is administered. This requires a thorough investigation of the pituitary function.
Use in pregnancy: Clinical experience of use in pregnant women is limited. Animal experimental data are incomplete. Therefore, Genotropin should be given to pregnant women only if clearly needed.
Use in lactation: Information is lacking on whether peptide hormones pass over into the breast milk, but absorption in the gastrointestinal tract of the infant of intact protein is extremely unlikely.
Caution should be exercised when Genotropin is administered to a nursing woman.